What Does GATA3 Positive Mean in a Pathology Report?

A GATA3-positive result on a pathology report means the cells in your tissue sample are producing a protein called GATA3, and pathologists use that finding primarily to help determine where a tumor originated. In most clinical contexts, GATA3 positivity points toward breast cancer or urothelial carcinoma (cancer of the bladder or urinary tract lining), though a handful of other tumor types also stain positive. The result is one piece of a larger diagnostic puzzle, not a standalone diagnosis, and its meaning shifts depending on the clinical scenario and what other markers are tested alongside it.

Why Pathologists Test for GATA3

GATA3 is a transcription factor, a protein that switches genes on and off during cell development. It plays a central role in how certain tissues mature and function, particularly in the breast, urinary tract lining, skin, parts of the kidney, the parathyroid gland, and specific immune cells.¹ Because GATA3 is active in only a limited set of normal tissues, cancers that arise from those tissues tend to keep producing it even after they spread to distant sites. That persistence makes GATA3 useful when a pathologist is examining a metastatic tumor and trying to figure out where in the body it started.

In normal tissue, GATA3 shows up in the urothelium (bladder lining), breast gland cells, skin, hair follicles, parathyroid gland, placental cells, parts of the kidney, and certain lymphocytes.² When a pathologist orders a GATA3 immunohistochemical stain, they are applying an antibody to the tissue slide that binds to GATA3 protein and makes it visible under the microscope. If the tumor cell nuclei light up with the stain, the result is reported as positive.

GATA3 in Breast Cancer

Breast cancer is the setting where GATA3 testing comes up most often. The protein is expressed in a large majority of breast cancers, and it outperforms older breast markers in sensitivity. One study found GATA3 staining in about 83% of invasive breast cancers overall, compared with roughly 24% for GCDFP-15 and 47% for mammaglobin, two other markers traditionally used to confirm breast origin.³ That advantage is why GATA3 has become a go-to marker when a pathologist suspects that a tumor found in the lung, liver, bone, or lymph nodes might be a breast cancer metastasis.

The sensitivity varies by breast cancer subtype. Luminal cancers, the hormone receptor-positive types that make up the majority of breast cancers, are GATA3-positive in roughly 94% of cases. HER2-overexpressing cancers show lower rates, around 60%, and triple-negative breast cancers are positive in only about 38%.³ So a GATA3-negative result does not rule out breast cancer entirely, especially in more aggressive subtypes. When the clinical suspicion is high, pathologists often use a combination of markers. A panel that includes GATA3, mammaglobin, and SOX10 captures both hormone receptor-positive and hormone receptor-negative breast cancers more reliably than any single stain alone.⁴

In serous effusions, fluid samples from the chest or abdomen where cancer cells are floating, GATA3 has shown about 90% sensitivity for metastatic breast carcinoma.⁵ That kind of reliability matters in real-world practice, where a patient may show up with fluid buildup and no known cancer history, and the pathologist needs to narrow down the source quickly.

GATA3 in Bladder and Urinary Tract Cancers

Urothelial carcinoma is the other major tumor type defined by GATA3 positivity. The bladder lining normally expresses GATA3 at high levels, and cancers arising from it tend to retain the marker. Studies report positivity in about 77–85% of urothelial carcinomas.⁶ ⁷

This matters most when pathologists are trying to distinguish urothelial carcinoma from prostate cancer. Tumors near the bladder neck or prostatic urethra can look alike under the microscope, and getting the distinction right is critical because the two cancers are treated very differently. GATA3 helps: in one study, 85% of urothelial carcinomas were GATA3-positive while none of the prostate adenocarcinomas stained positive.⁷ Another study reported 100% specificity for urothelial carcinoma when using GATA3, meaning zero false positives among clear cell renal cell carcinoma and prostatic adenocarcinoma cases tested.⁸

One nuance: as urothelial cancers become more aggressive and lose their typical appearance (called divergent differentiation, where the tumor starts to look like squamous cell carcinoma or other variants), GATA3 expression can drop. In one study, about 77% of bladder carcinomas with variant histology still stained positive, but the staining intensity was sometimes weaker compared to conventional urothelial carcinoma.⁶ Interestingly, metastatic deposits in lymph nodes sometimes stained more intensely than the primary bladder tumor.

Other Tumors That Stain GATA3-Positive

Breast and urothelial cancers get most of the attention, but GATA3 is not exclusive to them. Several other tumor types can light up on a GATA3 stain, and pathologists need to keep these in mind to avoid misidentification.

Paragangliomas and pheochromocytomas, tumors of the autonomic nervous system, are strongly GATA3-positive. One study found GATA3 expression in about 89% of paragangliomas and 95% of pheochromocytomas, as well as in all neuroblastomas, ganglioneuroblastomas, and ganglioneuromas tested.⁹ Parathyroid tumors also consistently express GATA3, which makes sense given the protein’s normal role in parathyroid gland development.

Beyond those, GATA3 has been reported at low rates in some squamous cell carcinomas, certain salivary gland tumors, and occasional skin adnexal tumors. Salivary gland tumors are worth noting because breast and salivary gland tissue share developmental origins, so some overlap in marker expression is expected.¹⁰ A tissue microarray study covering over 16,000 tumors also noted GATA3 in some sebaceous gland tumors, hair follicle tumors, and a fraction of lymphocytes.¹¹

When GATA3 Positivity Can Be Misleading

No immunohistochemical marker is perfect, and GATA3 has known pitfalls that pathologists must navigate. The most clinically significant one involves paragangliomas of the urinary bladder. These rare tumors arise from nerve tissue in the bladder wall and are GATA3-positive in about 83% of cases.¹² Because the tumor is sitting in the bladder and staining positive for a urothelial marker, a pathologist unfamiliar with this pattern could misdiagnose it as urothelial carcinoma. The distinction matters enormously: bladder paragangliomas are treated and followed up very differently from bladder cancer.

Prostate cancer is another area where GATA3 can occasionally cause confusion. While large studies show zero GATA3 positivity in prostatic adenocarcinoma, rare cases with strong aberrant GATA3 staining have been described.¹³ Benign prostate glands treated with radiation therapy can also pick up GATA3 staining, adding another layer of complexity for pathologists evaluating post-treatment biopsies.¹⁴

Sporadic positivity shows up in unexpected places too. Among tumors that are not breast or urothelial in origin, about 6% stained GATA3-positive in one cytology series, including a metastatic ovarian serous carcinoma, a squamous cell carcinoma, a skin adnexal carcinoma, and a thymic carcinoma.¹⁵ These exceptions are uncommon, but they are real, which is why pathologists never rely on a single stain to make a diagnosis.

What GATA3 Means for Prognosis

Beyond telling pathologists where a tumor came from, GATA3 also carries prognostic information, at least in breast cancer. Multiple studies have found that higher GATA3 expression is linked to better outcomes. In one analysis with a median follow-up of over 15 years, GATA3-positive breast cancers had better overall survival, with a hazard ratio of 0.70, meaning roughly 30% lower risk of death during follow-up.¹⁶ That survival advantage was strongest in patients with lower-grade, earlier-stage, hormone receptor-positive disease.

A gene expression meta-analysis found an even starker difference: ten-year disease-free survival was 84% in patients with high GATA3 expression compared with 55% in those with low expression.¹⁷ Low GATA3 was an independent predictor of worse outcomes even after accounting for other prognostic features like tumor size, grade, and lymph node status.¹⁸

Part of this is likely because GATA3 tracks closely with hormone receptor positivity and lower tumor grade. Tumors that express GATA3 tend to be estrogen receptor-positive, progesterone receptor-positive, and lower in mitotic rate. Luminal A breast cancers, the subtype with the best prognosis overall, have the highest frequency of GATA3 positivity.¹⁶ But statistical analyses suggest GATA3 adds prognostic information beyond what you get from those standard markers alone, meaning it captures something about tumor biology that hormone receptor status by itself does not fully explain.

In bladder cancer, the picture is somewhat reversed in terms of what losing GATA3 means. Laboratory research has shown that knocking out GATA3 in bladder cancer cell lines promotes cell migration and invasion, with increases in proteins associated with tumor spread. GATA3 loss also correlated with shifts from epithelial to mesenchymal cell characteristics, a change associated with more aggressive behavior.¹⁹ High-grade invasive bladder cancers are more likely to have lost GATA3, consistent with the protein acting as a brake on tumor progression in that tissue too.

What If the Tumor Is GATA3-Negative

A negative GATA3 result does not rule out breast or urothelial cancer. As discussed, roughly one in five urothelial carcinomas and about 17% of all invasive breast cancers will not stain positive. The likelihood of a false negative rises with certain tumor characteristics. Triple-negative breast cancers and basal-like breast cancers are GATA3-negative far more often than luminal subtypes, with basal-like tumors positive in as few as 1 out of 42 cases in one series. ³ For high-grade, poorly differentiated urothelial carcinomas, the drop-off is similar.

When GATA3 is negative but clinical suspicion remains, pathologists turn to additional markers. For breast cancer, SOX10 is particularly useful because it picks up triple-negative and basal-like breast cancers that GATA3 misses.⁴ For urothelial carcinoma, uroplakin and p63 are common additions to the panel. The overarching principle is that no single marker works alone. Pathologists assemble panels of several stains and interpret the pattern collectively, alongside the patient’s imaging, clinical history, and the tumor’s microscopic appearance.

GATA3 Mutations Versus GATA3 Expression

Seeing “GATA3 positive” on a pathology report typically refers to protein expression detected by immunohistochemistry, the staining technique described throughout this article. But GATA3 also shows up in a different context: somatic mutations. The GATA3 gene is one of the most frequently mutated genes in estrogen receptor-positive breast cancer. These are acquired mutations in the tumor itself, not inherited conditions.

Tumors with GATA3 mutations can behave differently from those with normal GATA3 genes. Research has identified a subset of hormone receptor-positive breast cancer patients with GATA3 deficiency who respond poorly to hormonal therapy and have a worse prognosis.²⁰ One line of investigation has found that GATA3 and a protein called MDM2 have a synthetic lethal relationship in ER-positive breast cancers, meaning that when GATA3 is deficient, targeting MDM2 could selectively kill those cancer cells. This is still in early-stage research, but it hints at future treatment strategies that use GATA3 mutation status to guide drug selection.

Germline GATA3 mutations (present in every cell of the body, not just the tumor) are far rarer and cause a condition called HDR syndrome, characterized by hypoparathyroidism, sensorineural deafness, and kidney abnormalities. In a genomic profiling study of metastatic hormone receptor-positive breast cancers, no GATA3 alterations appeared to be germline based on their allele frequency.²¹ If your report mentions a GATA3 mutation found through genomic testing, that is a separate finding from GATA3 immunohistochemistry and should be interpreted in the context of the genomic panel and your oncologist’s treatment planning.

GATA3’s Role in the Immune System

If you dig deeper into your medical records or the scientific literature, you may encounter references to GATA3 outside of cancer entirely. GATA3 is widely recognized as a master regulator of a specific type of immune cell called the T helper 2 (Th2) cell.²² Th2 cells are part of the adaptive immune response and play key roles in fighting parasitic infections and in allergic responses. GATA3 controls the expression of immune signaling molecules like interleukins IL-4, IL-5, and IL-13.²³

This immune function has implications for tumor biology that researchers are still working out. The composition of immune cells within and around a tumor, the tumor microenvironment, affects how cancers grow and respond to treatment. GATA3’s dual involvement in both the tumor cells themselves and the immune cells that infiltrate the tumor creates a complicated picture. In breast cancer pathology reports, GATA3 staining is being evaluated in the tumor cells, not the surrounding immune cells. But the protein’s broader role in immune regulation helps explain why it keeps showing up in research across so many different biological contexts. GATA3 is not limited to the Th2 story either; it has essential functions at earlier stages of blood cell and lymphocyte development, well before mature immune cells specialize.²⁴

How to Read GATA3 Results on Your Own Report

Pathology reports can be dense documents, and seeing an unfamiliar marker like GATA3 can be unsettling. Here is what to look for in practical terms.

The report will typically describe GATA3 staining as positive or negative, sometimes with a note about intensity (weak, moderate, strong) and the percentage of tumor cells staining. Strong nuclear staining in a majority of tumor cells is considered a clear positive. Weak or focal staining, where only scattered cells light up, can be harder to interpret and may warrant additional testing.

Context determines what the result means for you. If the pathologist is evaluating a known breast cancer, GATA3 positivity confirms the breast origin and aligns with a better prognosis, especially in hormone receptor-positive disease. If the biopsy is from a bladder tumor, GATA3 positivity supports a urothelial origin and helps rule out prostate cancer or other mimics. If the sample is from an unexpected site, a mass in the liver or lymph node found on imaging, GATA3 positivity narrows the likely source to a short list, with breast and urothelial cancer at the top.

GATA3 will almost always appear alongside other immunohistochemical markers on the report. In a breast cancer workup, you might see it alongside estrogen receptor, progesterone receptor, HER2, and Ki-67. In a bladder cancer scenario, it might sit next to p63, CK20, CK7, or uroplakin markers. The pathologist interprets the full panel together, and the final diagnosis in the report’s summary reflects that combined analysis. If you are trying to understand what GATA3 means for your specific situation, the most useful line to focus on is the pathologist’s interpretive summary at the end, not the individual stain result in isolation.

1
PubMed. GATA3: Orchestrating cellular fate through differentiation and proliferation
2
PubMed Central. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors
3
PubMed. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer
4
Journal of Molecular Pathology. Comparison of GATA3, GCDFP15, Mammaglobin and SOX10 Immunocytochemistry in Aspirates of Metastatic Breast Cancer
5
PubMed. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens
6
PubMed Central. Diagnostic Relevance of GATA 3 Expression in Urinary Bladder Carcinoma of Divergent Differentiation and Other Histological Variants
7
Journal of Pathology and Translational Medicine. Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma
8
Indian Journal of Pathology and Microbiology. Diagnostic utility of GATA3 immunohistochemical expression in urothelial carcinoma
9
The American Journal of Surgical Pathology. A Study of Gata3 and Phox2b Expression in Tumors of the Autonomic Nervous System
10
Head and Neck Pathology. GATA3 Immunohistochemical Expression in Salivary Gland Neoplasms
11
Pathobiology. GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors
12
PubMed. GATA3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma
13
PubMed. Aberrant GATA3 Staining in Prostatic Adenocarcinoma: A Potential Diagnostic Pitfall
14
PubMed. GATA3 expression in benign prostate glands with radiation atypia: a diagnostic pitfall
15
PubMed. Utility and pitfalls of GATA3 immunocytochemistry for diagnosis of metastatic breast carcinoma and urothelial carcinoma on cytology specimens
16
PubMed Central. GATA3 as an Adjunct Prognostic Factor in Breast Cancer Patients with Less Aggressive Disease: A Study with a Review of the Literature
17
Cancer Research. Identification of GATA3 as a Breast Cancer Prognostic Marker by Global Gene Expression Meta-analysis
18
PubMed Central. Higher levels of GATA3 predict better survival in women with breast cancer
19
PubMed Central. Loss of GATA3 in bladder cancer promotes cell migration and invasion
20
PubMed Central. GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers
21
PubMed Central. Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes
22
PubMed Central. GATA3: a master of many trades in immune regulation
23
Immunity. Diverse Function of GATA-3 in Lymphocyte Development and Immunity
24
PubMed Central. GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation